Literature DB >> 32787683

Development and validation of an oxidative phosphorylation-related gene signature in lung adenocarcinoma.

Zihao Xu1,2, Zilong Wu1, Jingtao Zhang1, Ruihao Zhou3, Ling Ye3, Pingliang Yang4, Bentong Yu1.   

Abstract

Aim: To develop an oxidative phosphorylation (OXPHOS)-related gene signature of lung adenocarcinoma (LUAD). Materials & methods: We split The Cancer Genome Atlas LUAD cohort into a training set and a test set; we used the least absolute shrinkage and selection operator Cox method to structure the OXPHOS-related prognostic signature in the training set and verified in the test set and GSE30219 dataset. Meanwhile, the diagnostic model was constructed using the logistic Cox method.
Results: The signature consisted of seven genes (LDHA, CFTR, HSPD1, SNHG3, MAP1LC3C, COX6B2, and TWIST1). LUAD patients were divided into high- and low-risk groups, demonstrating good diagnostic and prognostic capabilities.
Conclusion: We developed the first-ever OXPHOS-related signature with both prognostic predictive power and diagnostic efficacy.

Entities:  

Keywords:  diagnostic signature; lung adenocarcinoma; oxidative phosphorylation; prognostic signature

Year:  2020        PMID: 32787683     DOI: 10.2217/epi-2020-0217

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  5 in total

Review 1.  Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer.

Authors:  Ping Yang; Yingnan Qiao; Mei Meng; Quansheng Zhou
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

2.  Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.

Authors:  Yang Zhai; Bin Zhao; Yuzhen Wang; Lina Li; Jingjin Li; Xu Li; Linhan Chang; Qian Chen; Zijun Liao
Journal:  BMC Cancer       Date:  2021-03-01       Impact factor: 4.430

3.  Immunotherapeutic Value of MAP1LC3C and Its Candidate FDA-Approved Drugs Identified by Pan-Cancer Analysis, Virtual Screening and Sensitivity Analysis.

Authors:  Xudong Zhang; Kunhang Li; Shiyu Zhong; Shengyu Liu; Tao Liu; Lishuai Li; Shuo Han; Qingqing Zhai; Nan Bao; Xin Shi; Yijun Bao
Journal:  Front Pharmacol       Date:  2022-03-02       Impact factor: 5.810

4.  Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.

Authors:  Jinhui Liu; Tian Chen; Min Yang; Zihang Zhong; Senmiao Ni; Sheng Yang; Fang Shao; Lixin Cai; Jianling Bai; Hao Yu
Journal:  Front Cell Dev Biol       Date:  2021-11-25

5.  Exploring YAP1-centered networks linking dysfunctional CFTR to epithelial-mesenchymal transition.

Authors:  Margarida C Quaresma; Hugo M Botelho; Ines Pankonien; Cláudia S Rodrigues; Madalena C Pinto; Pau R Costa; Aires Duarte; Margarida D Amaral
Journal:  Life Sci Alliance       Date:  2022-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.